Suppr超能文献

血清铁蛋白是中国骨髓增生异常综合征患者(国际预后评分系统为中危-1 组)的独立预后因素。

Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS Intermediate-1.

机构信息

MDS and MPN Centre, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.

出版信息

Acta Haematol. 2013;129(4):243-50. doi: 10.1159/000345428. Epub 2013 Jan 15.

Abstract

BACKGROUND

The International Prognostic Staging System (IPSS) for myelodysplastic syndromes (MDS) was developed predominately in patients of European ancestry and is not validated in Asians. In a recently revised IPSS (IPSS-R), several new prognostic variables are included, i.e. age, Eastern Cooperative Oncology Group performance score (ECOG PS), serum ferritin and lactate dehydrogenase. Chinese with MDS offer a unique opportunity to distinguish the prognostic impacts of haemoglobin (HGB) concentration, red blood cell (RBC) transfusions and serum ferritin because in China, patients rarely receive RBC transfusions unless the HGB concentration is <6.0 g/dl.

METHODS

We studied prognostic variables in 191 untreated Chinese primary patients with MDS intermediate-1 (INT-1) in the IPSS.

RESULTS

Serum ferritin level ≥500 µg/l at diagnosis was a strong independent predictor of survival. Although baseline serum ferritin level was inversely correlated with baseline HGB, it was the serum ferritin, not the baseline HGB level, that was significantly correlated with survival in Chinese patients. A new prognostic scoring system including the ECOG PS, absolute neutrophil level, serum ferritin, percentage of bone marrow blasts and poor karyotype was developed for Chinese with IPSS INT-1 MDS.

CONCLUSIONS

This revised scoring system identified a subgroup of Chinese with MDS and INT-1 IPPS who have a poor prognosis and may benefit from more intensive therapy.

摘要

背景

骨髓增生异常综合征(MDS)的国际预后评分系统(IPSS)主要是在欧洲血统的患者中开发的,在亚洲人群中尚未得到验证。在最近修订的 IPSS(IPSS-R)中,纳入了几个新的预后变量,如年龄、东部合作肿瘤学组表现评分(ECOG PS)、血清铁蛋白和乳酸脱氢酶。中国 MDS 患者提供了一个独特的机会,可以区分血红蛋白(HGB)浓度、红细胞(RBC)输注和血清铁蛋白的预后影响,因为在中国,患者很少接受 RBC 输注,除非 HGB 浓度<6.0 g/dl。

方法

我们研究了 191 例未经治疗的中国 MDS 中间-1(INT-1)患者的预后变量。

结果

诊断时血清铁蛋白水平≥500 µg/l 是生存的独立强预测因素。尽管基线血清铁蛋白水平与基线 HGB 呈负相关,但与中国患者生存相关的是血清铁蛋白,而不是基线 HGB 水平。为 IPSS INT-1 MDS 中国患者开发了一个新的预后评分系统,包括 ECOG PS、绝对中性粒细胞水平、血清铁蛋白、骨髓原始细胞百分比和不良核型。

结论

这个修订后的评分系统确定了一组中国 MDS 和 INT-1 IPPS 患者预后不良,可能受益于更强化的治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验